RFA
SONN

Reilly Financial Advisors’s Sonnet BioTherapeutics SONN Stock Holding History

Reilly Financial Advisors’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2
Closed -$14K – 922
2020
Q3 		$14K Buy
2
+1
+100% +$7.21K ﹤0.01% 516
2020
Q2 		$8K Buy
+1
New +$11.6K ﹤0.01% 639

Other funds holding SONN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MSFS
Main Street Financial Solutions Newtown, Pennsylvania $1.34B AUM 19.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Reilly Financial Advisors's SONN Position: Q4 2020 in Review

Reilly Financial Advisors sold out of Sonnet BioTherapeutics (SONN) in Q4 2020, closing a stake of 2 shares — an estimated $14K sold.

Reilly Financial Advisors first reported a position in SONN in Q2 2020 and held it in 2 quarters. The position peaked at $14K in Q3 2020. 8 funds tracked by Wall St. Rank hold SONN as of Q4 2020.

  • Reilly Financial Advisors reported no remaining Sonnet BioTherapeutics position as of Q4 2020 after selling out during the quarter.
  • Reilly Financial Advisors sold 2 Sonnet BioTherapeutics shares in Q4 2020, an estimated $14K.
  • Reilly Financial Advisors first reported a position in Sonnet BioTherapeutics in Q2 2020 and held it in 2 quarters.
  • Reilly Financial Advisors's Sonnet BioTherapeutics position peaked at $14K in Q3 2020.
  • 8 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2020.

Based on Reilly Financial Advisors's 13F filing for Q4 2020, filed 3 Feb 2021.